|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"coumar ms"
Showing items 1-50 of 71 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2025-01 |
Aldehyde dehydrogenases as drug targets for cancer: SAR and structural biology aspects for inhibitor design
|
Tahiliani, H;Dhayalan, A;Li, MC;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2023-02-07 |
Development of furanopyrimidine-based orally active third- generation EGFR inhibitors for the treatment of non-small cell lung cancer
|
Li, MC;Coumar, MS;Lin, SY;Lin, YS;Huang, GL;Chen, CH;Lien, TW;Wu, YW;Chen, YT;Chen, CP;Huang, YC;Yeh, KC;Yang, CM;Kalita, B;Pan, SL;Hsu, TA;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2022-02-07 |
Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer
|
Li, MC;Coumar, MS;Lin, SY;Lin, YS;Huang, GL;Chen, CH;Lien, TW;Wu, YW;Chen, YT;Chen, CP;Huang, YC;Yeh, KC;Yang, CM;Kalita, B;Pan, SL;Hsu, TA;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2022-02 |
What can the anti-apoptotic molecule, BIRC5/Survivin, do in the autophagic world?
|
Cheung, CH;Lin, TY;Sarvagalla, S;Coumar, MS;Cheng, SM;Leung, E |
| 國家衛生研究院 |
2021-04-16 |
Development of a robust scale-up synthetic route for BPR1K871: A clinical candidate for the treatment of acute myeloid leukemia and solid tumors
|
Reddy, JS;Chen, CM;Coumar, MS;Sun, HY;Sun, N;Hsieh, HP |
| 國家衛生研究院 |
2021-02-22 |
Mimicking H3 substrate arginine in the design of G9a lysine methyltransferase inhibitors for cancer therapy: A computational study for structure-based drug design
|
Chandar Charles, MR;Li, MC;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2020-08 |
The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells
|
Chang, YC;Kondapuram, SK;Yang, TH;Syed, SB;Cheng, SM;Lin, TY;Lin, YC;Coumar, MS;Chang, JY;Leung, E;Cheung, CHA |
| 國家衛生研究院 |
2020-07-07 |
Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors
|
Syed, SB;Lin, SY;Arya, H;Fu, IH;Yeh, TK;Charles, MRC;Periyasamy, L;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2020-05 |
Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors
|
Lin, SY;Chang, CF;Coumar, MS;Chen, PY;Kuo, FM;Chen, CH;Li, MC;Lin, WH;Kuo, PC;Wang, SY;Li, AS;Lin, CY;Yang, CM;Yeh, TK;Song, JS;Hsu, JTA;Hsieh, HP |
| 國家衛生研究院 |
2020-01 |
Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening
|
Chandar Charles, MR;Mahesh, A;Lin, SY;Hsieh, HP;Dhayalan, A;Coumar, MS |
| 國家衛生研究院 |
2019-10-15 |
BIRC5/Survivin is a novel ATG12?ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells
|
Lin, TY;Chan, HH;Chen, SH;Sarvagalla, S;Chen, PS;Coumar, MS;Cheng, SM;Chang, YC;Lin, CH;Leung, E;Cheung, CHA |
| 國家衛生研究院 |
2019-10-15 |
BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells
|
Lin, TY;Chan, HH;Chen, SH;Sarvagalla, S;Chen, PS;Coumar, MS;Cheng, SM;Chang, YC;Lin, CH;Leung, E;Cheung, CHA |
| 國家衛生研究院 |
2019-09 |
Design of a potent anticancer lead inspired by natural products from traditional Indian medicine
|
Arya, H;Yadav, CS;Lin, SY;Syed, SB;Charles, MRC;Kannadasan, S;Hsieh, HP;Singh, SS;Gajurel, PR;Coumar, MS |
| 國家衛生研究院 |
2019-05-29 |
Insights for the design of protein lysine methyltransferase G9a inhibitors
|
Charles, MRC;Dhayalan, A;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2018-07-26 |
Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: A molecular dynamics study
|
M, RCC;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2017-08-11 |
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer
|
Syed, SB;Arya, H;Fu, IH;Yeh, TK;Periyasamy, L;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2017-07 |
Drug repurposing for chronic myeloid leukemia: In silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors
|
Singh, VK;Chang, HH;Kuo, CC;Shiao, HY;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2017-01-13 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2016-11-23 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2016-07 |
Therapeutic polymeric nanoparticles and the methods of making and using thereof: A patent evaluation of WO2015036792
|
Sarvagalla, S;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2016-06-07 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2016-03 |
Disruption of protein-protein interactions: Hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target survivin
|
Sarvagalla, S;Cheung, CHA;Tsai, JY;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2015-08-20 |
Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors
|
Coumar, MS;Chao, YS;Hsu, TA;Wu, SY;Hsieh, HP |
| 國家衛生研究院 |
2015-07-31 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Wu, SY;Hsu, TA;Chao, YS |
| 國家衛生研究院 |
2015-07-22 |
作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Lin, WH;Chen, YR;Chao, YS |
| 國家衛生研究院 |
2015-06-29 |
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
|
Ke, YY;Singh, VK;Coumar, MS;Hsu, YC;Wang, WC;Song, JS;Chen, CH;Lin, WH;Wu, SH;Hsu, JT;Shih, C;Hsieh, HP |
| 國家衛生研究院 |
2015-04-14 |
Fused multicyclic compounds as protein kinase inhibitors
|
Hsieh, HP;Coumar, MS;Chao, YS |
| 國家衛生研究院 |
2015-01 |
Identification of ligand efficient, fragment-like hits from an HTS library: Structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
|
Sarvagalla, S;Singh, VK;Ke, YY;Shiao, HY;Lin, WH;Hsieh, HP;Hsu, JTA;Coumar, MS |
| 國家衛生研究院 |
2014-10-29 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2014-08 |
Ligand efficiency based approach for efficient virtual screening of compound libraries
|
Ke, YY;Coumar, MS;Shiao, HY;Wang, WC;Chen, CW;Song, JS;Chen, CH;Lin, WH;Wu, SH;Hsu, JT;Chang, CM;Hsieh, HP |
| 國家衛生研究院 |
2014-03-20 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2014-03 |
Efficient virtual screening using ligand efficiency based approach
|
Hsieh, HP;Ke, YY;Coumar, MS;Lin, WH;Wang, WC;Shiao, HY;Hsu, TAJ |
| 國家衛生研究院 |
2013-07-01 |
做為蛋白質激酶抑制劑之稠合多環化合物
|
Hsieh, HP;Coumar, MS;Chao, YS |
| 國家衛生研究院 |
2013-06-28 |
Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine aurora kinase inhibitor
|
Shiao, HY;Coumar, MS;Chang, CW;Ke, YY;Chi, YH;Chu, CY;Sun, HY;Chen, CH;Lin, WH;Fung, KS;Kuo, PC;Huang, CT;Chang, KY;Lu, CT;Hsu, JT;Chen, CT;Jiaang, WT;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2013-05 |
Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules
|
Wu, JM;Chen, CT;Coumar, MS;Lin, WH;Chen, ZJ;Hsu, JT;Peng, YH;Shiao, HY;Chu, CY;Wu, JS;Lin, CT;Chen, CP;Hsueh, CC;Chang, KY;Kao, LP;Huang, CY;Chao, YS;Wu, SY;Hsieh, HP;Chi, YH |
| 國家衛生研究院 |
2013-05 |
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: The role of the DFG motif in the design of epidermal growth factor receptor inhibitors
|
Peng, YH;Shiao, HY;Tu, CH;Liu, PM;Hsu, JT;Amancha, PK;Wu, JS;Coumar, MS;Chen, CH;Wang, SY;Lin, WH;Sun, HY;Chao, YS;Lyu, PC;Hsieh, HP;Wu, SY |
| 國家衛生研究院 |
2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor
|
Ke, YY;Shiao, HY;Hsu, YC;Chang-Chu, Y;Wang, WC;Lee, YC;Lin, WH;Hsu, JTA;Chang, CW;Lin, CW;Yeh, TK;Chao, YS;Coumar, MS;Hsieh, HP |
| 國家衛生研究院 |
2013-02-11 |
作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Chao, YS;Hsu, TA;Lin, WH;Chen, YR |
| 國家衛生研究院 |
2013-01 |
3D-QSAR-assisted drug design: Identification of a potent quinazoline-based aurora kinase inhibitor
|
Ke, YY;Shiao, HY;Hsu, YC;Chu, CY;Wang, WC;Lee, YC;Lin, WH;Chen, CH;Hsu, JTA;Chang, CW;Lin, CW;Yeh, TK;Chao, YS;Coumar, MS;Hsieh, HP |
| 國家衛生研究院 |
2012-09 |
Anti-influenza drug discovery: Identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimization
|
Yeh, JY;Coumar, MS;Shiao, HY;Lin, TJ;Lee, YC;Hung, HC;Ko, S;Kuo, FM;Fang, MY;Huang, YL;Hsu, JT;Yeh, TK;Shih, SR;Chao, YS;Horng, JT;Hsieh, HP |
| 國家衛生研究院 |
2012-05-11 |
作為極光激酶抑制劑之稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2012-03-20 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2011-09-23 |
BPR1K653, a novel Aurora Kinase Inhibitor, exhibits potent anti-proliferative activity in P-gp170 (MDR1)-mediated VX680-resistant cancer cells in vitro and in vivo
|
Hsieh, HP;Cheung, CHA;Lin, WH;Hsu, TA;Coumar, MS;Chao, YS;Chang, JY |
| 國家衛生研究院 |
2011-08 |
BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells
|
Cheung, CH;Lin, WH;Hsu, TA;Hour, TC;Yeh, TK;Ko, S;Lien, TW;Coumar, MS;Liu, JF;Lai, WY;Shiao, HY;Lee, TR;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2011-06 |
Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10)
|
Cheung, CHA;Coumar, MS;Chang, JY;Hsieh, HP |
| 國家衛生研究院 |
2011-04-28 |
Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-Fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents
|
Tung, YS;Coumar, MS;Wu, YS;Shiao, HY;Chang, JY;Liou, JP;Shukla, P;Chang, CW;Chang, CY;Kuo, CC;Yeh, TK;Lin, CY;Wu, JS;Wu, SY;Liao, CC;Hsieh, HP |
| 國家衛生研究院 |
2010-12 |
Discovery of non-glycoside sodium-dependent glucose Co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
|
Wu, JS;Peng, YH;Wu, JM;Hsieh, CJ;Wu, SH;Coumar, MS;Song, JS;Lee, JC;Tsai, CH;Chen, CT;Liu, YW;Chao, YS;Wu, SY |
| 國家衛生研究院 |
2010-10-28 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency
|
Wu, CH;Coumar, MS;Chu, CY;Lin, WH;Chen, YR;Chen, CT;Shiao, HY;Rafi, S;Wang, SY;Hsu, H;Chen, CH;Chang, CY;Chang, TY;Lien, TW;Fang, MY;Yeh, KC;Chen, CP;Yeh, TK;Hsieh, SH;Hsu, JT;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-10 |
Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists
|
Peng, YH;Coumar, MS;Leou, JS;Wu, JS;Shiao, HY;Lin, CH;Lin, WH;Lien, TW;Chen, X;Hsu, JT;Chao, YS;Huang, CF;Lyu, PC;Hsieh, HP;Wu, SY |
| 國家衛生研究院 |
2010-08 |
Lead optimization of furanopyrimidine Aurora kinase inhibitors: Development of in vivo active agents in tumor xenograft models
|
Hsieh, HP;Chu, CY;Coumar, MS;Lin, WH;Chen, CT;Hsu, TA;Wu, SY;Chao, YS |
Showing items 1-50 of 71 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
